MA-MEIJI-SEIKA-PHARMA
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi), a leading Japanese pharmaceutical company specializing in infectious diseases, vaccines, and hematology, announced today that it has established a new office in the Boston area, USA, and is initiating venture investments in the life science and healthcare fields. Through its investment activities, Meiji Seika Pharma aims to discover and develop cutting-edge therapies and contribute to solving unmet medical needs of patients worldwide, reflecting the company’s unwavering commitment to innovation and global health.
Meiji Seika Pharma was founded in 1916, started pharmaceutical business in 1946, and has grown to be a leading Japanese pharmaceutical company. The company has been at the forefront of research and development of therapeutics and vaccines for infectious diseases. In December 2023, Meiji Seika Pharma obtained the world’s first marketing approval for a self-amplifying mRNA vaccine against COVID-19 (Kostaive®). In addition to its focus on infectious diseases area, Meiji Seika Pharma is dedicated to drug discovery and development in hematology and oncology. The company has developed and launched a selective ROCK2 inhibitor (belumosudil mesilate) for the treatment of chronic GVHD, and an HDAC inhibitor (tucidinostat) for ATLL and PTCL in Japan. As a fully integrated pharmaceutical company, it has over 5,500 employees worldwide.
Meiji Seika Pharma will expand its presence in the Boston area by opening a new office and explore venture investments at the center of innovation. Located at CIC Cambridge (One Broadway, Cambridge, MA 02142), the new office will act as a strategic hub, fostering investment opportunities that align with the Meiji Seika Pharma’s current vision for growth and innovation. Meiji Seika Pharma will initiate investments in startups and venture capital firms that focus on drug discovery and innovative platform technology. The office is organized as part of Meiji Pharma USA Inc., a subsidiary of Meiji Seika Pharma.
“We are pleased to deepen our expertise in infectious diseases area as well as other focus areas,” said Mr. Daikichiro Kobayashi, President and Representative Director of Meiji Seika Pharma. “Our Boston office will facilitate collaboration with pioneering bioventures and startups, furthering our mission to develop innovative solutions such as groundbreaking therapeutics and beyond the pills.”
Meiji Seika Pharma’s challenges into these innovative approaches show its commitment to addressing critical health challenges and improving patient outcomes on a global scale. By leveraging the Boston area’s dynamic ecosystem, the company aims to accelerate its research and development efforts and bring breakthrough therapies to global market.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808269845/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Combined Shareholders’ Meeting of June 19, 2025: All Submitted Resolutions Were Adopted20.6.2025 07:00:00 CEST | Press release
The Combined Shareholders’ Meeting of Bureau Veritas (the "Company"), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company’s head office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619834393/en/ Hinda Gharbi, CEO Bureau Veritas All resolutions submitted to the Shareholders’ Meeting were adopted at a large majority, including: The approval of the statutory and consolidated financial statements for the financial year ending on December 31, 2024, and the approval of a dividend distribution of €0.90 per share to be paid in cash on July 3, 2025 (ex-date on July 1, 2025) on positions closed on July 2, 2025; The approval of a related-party agreement concerning the Company’s participation in Wendel’s share placement (acquisition by the Company of its own shares); The approval of the report on Corporate Officers’ compensation; The approval of fixed, variable and extraordinary compone
Hanshow Showcases Retail Media and Store Intelligence at 2025 CGF Global Summit19.6.2025 17:00:00 CEST | Press release
Hanshow, a global leader in digital retail solutions, underscored its leadership in AI, IoT, and Retail Media at the 2025 Global Summit of the Consumer Good Forum (CGF), held from June 11 to 13 at RAI Amsterdam. From an immersive ‘Future Store’ showcase in the I-Zone to moderating one of the Summit’s most anticipated panel discussions, Hanshow demonstrated how its integrated platform is driving the next wave of store transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619798164/en/ Inside the Future Store: Hanshow’s Real-Time Innovation at I-Zone At Booth No.8 in the I-Zone, Hanshow presented an interactive showcase themed “Powering Your Future Store,” highlighting four core pillars of the future store: real-time pricing and shelf operations powered by ESLs; smart carts that enhance the shopping experience with autonomous navigation and seamless checkout; GenAI-enabled journeys offering contextual promotions an
Grid Dynamics to Unveil Robotic Inspection Solution at Automatica 202519.6.2025 15:15:00 CEST | Press release
Key Takeaways: At Automatica 2025, Grid Dynamics will present TPGen—an AI robotic solution developed in partnership with Wandelbots to automate industrial robotic workflows that involve complex programming. The new solution dramatically reduces programming time—transforming what typically takes weeks of manual robot programming and analysis into automated processes completed in minutes through automatic tool-path generation based on CAD models. TPGen is built on top of the Wandelbots NOVA platform which enables seamless integration with a broad range of robotic manipulators. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a leading provider of technology consulting, platform and product engineering, AI, and digital‑engagement services—today announced it will showcase its TPGen robotic solution at Automatica 2025, the world's leading event for smart automation and robotics taking place in Munich, Germany from June 24-27, 2025. The TPGen solution from Grid Dynamics, developed
Experian Accelerates Migration to AWS to Drive Innovation with Generative AI19.6.2025 15:00:00 CEST | Press release
Global data and technology leader expands its cloud footprint to enhance performance and reliability, using AWS analytics and AI capabilities to give financial organizations access to real-time intelligence Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Experian, a global data and technology company, is embarking on the next phase of its cloud migration and has selected AWS as its preferred cloud. By leveraging AWS’s advanced cloud capabilities, Experian can provide faster, more scalable solutions that empower clients with deeper insights and more secure data services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619029263/en/ Experian's cloud first strategy, in partnership with AWS, accelerates innovation by enhancing performance, scalability, and reliability, while enabling the company to better serve its clients with innovative products and solutions. By migrating of
Greenland Resources Receives 30-Year Exploitation License for Molybdenum and Magnesium19.6.2025 14:52:00 CEST | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) and its fully owned Greenlandic subsidiary Greenland Resources A/S (“Greenland Resources” or the “Company”) is pleased to announce that today the Greenland’s Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, together with Dr. Ruben Shiffman, Chairman of the Board of Directors of Greenland Resources, signed a 30-year exploitation permit for molybdenum and magnesium for the Company’s Malmbjerg project in east Greenland (now defined as the Piiaaffik Høstakken). The Company can apply to extend the licence period up to 50-years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619915614/en/ Naalakkersuisut's Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, stated at the handover ceremony: "It is with great satisfaction that the Greenland Government can grant another exploit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom